Zuo Jinshi, Ren Jingyi, Yin Bowen, Wang Ziyi, Cui Qiqi, Liu Jiarui, Huang Dan, Pei Huanting, Wen Rui, Zhang Yadong, Ma Yuxia
Department of Nutrition and Food Hygiene, School of Public Health, Hebei Medical University, Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, 050017, China.
Undergraduate of College of Public Health, Hebei Medical University, Shijiazhuang, 050017, China.
Nutr Rev. 2025 Mar 1;83(3):e838-e851. doi: 10.1093/nutrit/nuae089.
As living standards have improved and lifestyles have undergone changes, metabolic diseases associated with obesity have become increasingly prevalent. It is well established that sesamin (Ses) (PubChem CID: 72307), the primary lignans in sesame seeds and sesame oil, possess antioxidant and anti-inflammatory effects.
In this study, a systematic review and meta-analysis of the effects of Ses on animal models of obesity-related diseases was performed to assess their impact on relevant disease parameters. Importantly, this study sought to provide insights for the design of future human clinical studies utilizing Ses as a nutritional supplement or drug.
This study conducted a comprehensive search in PubMed, Web of Science, Embase, Scopus, and the Cochrane Library, identifying English language articles published from inception to April 2023.
The search incorporated keywords such as "sesamin," "obesity," "non-alcoholic fatty liver disease," "type 2 diabetes mellitus," and "metabolic syndrome." The meta-analysis included 17 articles on non-alcoholic fatty liver disease, type 2 diabetes, and metabolic syndrome.
Overall, the pooled results demonstrated that Ses significantly reduced levels of total serum cholesterol (P = .010), total serum triglycerides (P = .003), alanine transaminase (P = .003), and blood glucose (P < .001), and increased high-density lipoprotein cholesterol levels (P = .012) in animal models of nonalcoholic fatty liver disease. In the type 2 diabetes model, Ses mitigated drug-induced weight loss (P < .001), high-fat-diet-induced weight gain (P < .001), and blood glucose levels (P = .001). In the metabolic syndrome model, Ses was associated with a significant reduction in body weight (P < .001), total serum cholesterol (P < .001), total serum triglycerides (P < .001), blood glucose (P < .001), and alanine transaminase levels (P = .039).
The meta-analysis results of this study suggest that Ses supplementation yields favorable effects in animal models of obesity-related diseases, including hypolipidemic, insulin-lowering, and hypoglycemic abilities, as well as organ protection from oxidative stress and reduced inflammation.
PROSPERO registration No. CRD42023438502.
随着生活水平的提高和生活方式的改变，与肥胖相关的代谢性疾病日益普遍。芝麻籽和芝麻油中的主要木脂素芝麻素（Ses）（PubChem CID：72307）具有抗氧化和抗炎作用，这一点已得到充分证实。
本研究对芝麻素对肥胖相关疾病动物模型的影响进行了系统评价和荟萃分析，以评估其对相关疾病参数的影响。重要的是，本研究旨在为未来将芝麻素用作营养补充剂或药物的人体临床研究设计提供见解。
本研究在PubMed、Web of Science、Embase、Scopus和Cochrane图书馆进行了全面检索，检索了从创刊至2023年4月发表的英文文章。
检索纳入了“芝麻素”、“肥胖”、“非酒精性脂肪性肝病”、“2型糖尿病”和“代谢综合征”等关键词。荟萃分析纳入了17篇关于非酒精性脂肪性肝病、2型糖尿病和代谢综合征的文章。
总体而言，汇总结果表明，在非酒精性脂肪性肝病动物模型中，芝麻素显著降低了总血清胆固醇水平（P = 0.010）、总血清甘油三酯水平（P = 0.003）、丙氨酸转氨酶水平（P = 0.003）和血糖水平（P < 0.001），并提高了高密度脂蛋白胆固醇水平（P = 0.012）。在2型糖尿病模型中，芝麻素减轻了药物诱导的体重减轻（P < 0.001）、高脂饮食诱导的体重增加（P < 0.001）和血糖水平（P = 0.001）。在代谢综合征模型中，芝麻素与体重显著降低（P < 0.001）、总血清胆固醇水平（P < 0.001）、总血清甘油三酯水平（P < 0.001）、血糖水平（P < 0.001）和丙氨酸转氨酶水平降低（P = 0.039）相关。
本研究的荟萃分析结果表明，补充芝麻素对肥胖相关疾病动物模型有有益影响，包括降血脂、降胰岛素和降血糖能力，以及对器官的氧化应激保护和炎症减轻作用。
PROSPERO注册号CRD42023438502。
